
doi: 10.1002/jca.20221
pmid: 19908304
AbstractBackground:Blood cell separators of the newest generation allow for the collection of high‐dose platelet concentrates. The aim of this study was to evaluate triple dose platelet collection with respect to feasibility and safety.Materials and Methods:Four hundred eighty plateletphereses were performed targeting to collect a triple platelet dose. Platelet counts were performed before and after apheresis and in platelet concentrates. Furthermore, donors were monitored for adverse events.Results:Triple dose platelet collection was achieved in 96% according to European and national guidelines. Mean donor platelet count before apheresis was 303 ± 64/nl and decreased to 195 ± 48/nl after plateletpheresis. The lowest platelet count after apheresis was 111/nl. Twenty‐one donor adverse events were observed (4.4%).Conclusions:Triple dose platelet collection is feasible and safe provided that donors are carefully checked for triple dose eligibility. J. Clin. Apheresis 2009. © 2009 Wiley‐Liss, Inc.
Adult, Male, Platelet Count, Plateletpheresis, Feasibility Studies, Humans, Female, Middle Aged
Adult, Male, Platelet Count, Plateletpheresis, Feasibility Studies, Humans, Female, Middle Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 10 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
